Table 3.
Comparison of liver studies at admission between cases and controls.
| Variables * | Normal Range | Age < 65 (n = 316) | Age ≥ 65 (n = 316) | p-Value |
|---|---|---|---|---|
| Fasting glucose (mmol/L) | 60–125 | 39.2% | 48.4% | 0.020 |
| ALT (U/L) | 7–35 | 41.5% | 56.3% | <0.001 |
| AST (U/L) | 10–40 | 40.2% | 57.6% | <0.001 |
| ALP (U/L) | 40–130 | 34.5% | 52.8% | <0.001 |
| Serum albumin (g/dL) | 3.4–5.4 | 31.3% | 36.1% | 0.206 |
| Total proteins (g/dL) | 6.0–8.3 | 26.3% | 30.4% | 0.251 |
| Total bilirubin (g/dL) | 0.3–1.2 | 20.6% | 25.6% | 0.131 |
| GGT (U/L) | 0–30 | 22.8% | 27.2% | 0.198 |
| LDH (U/L) | 140–280 | 27.8% | 38.0% | 0.006 |
| PT (seconds) | 11.0–13.5 | 28.8% | 34.5% | 0.123 |
| APTT (seconds) | 30–40 | 27.2% | 32.3% | 0.163 |
| FIB-4 | 1.45–3.25 | 26.3% | 40.5% | <0.001 |
| NFS | <−1.5 | 15.2% | 31.0% | <0.001 |
| APRI | 0.5–1.5 | 21.2% | 32.9% | <0.001 |
* Data reported as % outside the normal range and calculated using Chi-square test and Fisher’s exact unless specified differently; ALT—alanine aminotransferase; AST—aspartate aminotransferase; ALP—alkaline phosphatase; GGT—gamma glutamyl transpeptidase; LDH—lactate dehydrogenase; PT—prothrombin time; APTT—activated partial thromboplastin clotting time; FIB-4—Fibrosis-4 score; NFS—nonalcoholic fatty liver disease fibrosis score; APRI—AST to platelet ratio index.